Cipla Australia Pty

Cipla Australia Pty Ltd, a subsidiary of Cipla Limited, is a developer of oncology therapeutic drugs. The company's Hansoh Herceptin (Trastuzumab for Injection) has been approved by the Australian Therapeutic Goods Administration (TGA) for the treatment of HER2-positive early breast cancer, HER2-positive locally advanced breast cancer, HER2-overexpressing metastatic breast cancer, and HER2-positive advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. Its approved trade names in Australia are Tuzucip and Trastucip.